Person

Alan Crane

Alan Crane is a general partner at Polaris Partners with a focus on building and investing in healthcare companies since 2002. He has served as founder and/or has played a significant role as chairman and CEO in building six Polaris companies. From 2006 to present, Mr. Crane has co-founded and served as CEO of Cerulean Pharma (a clinical stage nanopharmaceutical company), co-founded Visterra, co-founded Calorics Pharmaceuticals (a company focused on nutrient sensing), and co-founded XTuit Pharmaceuticals (a company developing tumor microenvironment drugs). From 2002 to 2006, he was President and CEO of Momenta Pharmaceuticals (NASDAQ: MNTA). He joined Momenta as the fifth employee and built the company into a public company, creating an advanced and diversified pipeline, entering into two strategic collaborations with Novartis, and raising $275 million. The first product from Momenta's pipeline achieved over $1B during its first year of sales. Prior to Polaris, Mr. Crane was senior vice president of global corporate development at Millennium Pharmaceuticals. He was responsible for leading Millennium's strategic partnering, mergers and acquisitions, and licensing activities, generating over $2B in partner funding and acquiring 19 development stage products, including Velcade® which became the main basis of the company's $9B acquisition by Takeda. He serves on the boards of Cerulean Pharma (Chairman), T2 Biosystems, Ocular Therapeutix, Seventh Sense Biosystems, Calorics Pharmaceuticals (Chairman), XTuit Pharmaceuticals (Chairman), and Vaccinex. Previously, he served on the boards of Sirtris Pharmaceuticals (NASDAQ: SIRT, acquired by Glaxo SmithKline) and Adnexus (acquired by Bristol Myers Squibb). Mr. Crane received his MBA in 1992 and his BA summa cum laude and MA in 1986, all from Harvard University. He also attended Harvard Medical School from 1986 to 1988 before pursuing a business career.

Investors:

Website: http://www.visterrainc.com/

Email: [email protected]